ArticleACS applied bio materials2026
Heparinized Elastomeric Nanofibrillar Grafts: Mechanically Tunable, Cell-Supportive, and Thromboresistant Vascular Substitutes.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
The clinical success of vascular grafts relies on three main prerequisites: artery-tuned mechanics, a cell-supportive microstructure, and a thromboresistant interface. Most current solutions address only a subset of this triad and equate mechanical matching with compliance alone, which can lead to disturbed hemodynamics, maladaptive mechanobiology, and adverse graft-host biochemical interactions that frequently culminate in clinical complications and graft failure. This study presents polyurethane-based heparin-functionalized elastomeric nanofibrillar grafts (H-ENGs) that integrate all three prerequisites while allowing multi-parameter mechanical mimicry. To address the principal failure mode of early thrombosis, a small fraction of polyethyleneimine (PEI) is added to the ENG electrospinning solution to form P-ENGs, enabling one-step covalent heparin conjugation to form H-ENGs. The decoupled design of the ENG platform preserves the biomimetic microstructure and mechanics following PEI incorporation and heparinization, enabling adaptable, indication-specific optimization. In vitro, H-ENGs demonstrate strong benchtop performance, exhibiting a suture retention strength of 2.91 ± 0.40 N and a burst pressure of 634 ± 66 mmHg, both above physiological requirements. Relative to non-heparinized ENG controls, H-ENGs reduce the water contact angle from 117.3° to 90.6°, platelet adhesion density from 410 ± 61 to 35 ± 9 platelets/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.